Yazar "Bilici, A." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?(Elsevier Science Inc, 2019) Olmez, O. F.; Bilici, A.; Gursoy, P.; Cubukcu, E.; Yildiz, O.; Sakin, A.; Hamdard, J.[No abstract available]Öğe The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey(Amer Assoc Cancer Research, 2019) Bilici, A.; Menekse, S.; Akin, S.; Degirmenci, M.; Olmez, O. F.; Avci, N.; Sakalar, T.; Tural, D.; Kaplan, M. A.; Tanriverdi, O.; Bilgetekin, I.; Uslu, R.Öğe Graphene quantum dots-polyfluorene hybrid nanobiosensor for mitomycin C-DNA interaction sensing(Elsevier Ltd, 2024) Emre, D.; Denizhan, N.; Ozkan-Ariksoysal, D.; Bilici, A.; Sonkaya, Ö.; Algi, F.; Yilmaz, S.A novel graphene quantum dots (GQD) / polyfluorene (PF) nanocomposite was deposited on the disposable pencil tip graphite electrode (PGE) and proven to be an efficient nanosensor for analysis of the electrochemical interaction between the antitumor compound mitomycin C (MC) with double stranded DNA (ds-DNA). This modified electrode (GQD@PF-PGE) was prepared in four steps: hydrothermal, chemical oxidation, ultrasonication and electro-oxidation processes. GQD, PF, GQD@PF and GQD@PF-PGE have been characterized by different analytical techniques such as SEM, TEM, XRD, FTIR, UV–Vis, EIS. Compared to bare PGE, GQD@PF modified PGE performed approximately 56 times more sensitive analysis when evaluating the guanine oxidation signals measured by DPV. CV and EIS measurements also showed that GQD@PF-PGE possesses a fast electron transfer as compared to bare electrode and exhibit a remarkable electrocatalytic activity towards both guanine and MC electrooxidation. Comprehensive optimization studies have also been carried out for the developed new nanobiosensor. © 2023Öğe Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib(Elsevier Espana S.L.U, 2023) Olmez, O.F.; Bilici, A.; Gursoy, P.; Cubukcu, E.; Sakin, A.; Korkmaz, T.; Cil, I.Objectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib. Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (?934.7) SII scores. Multivariate analysis revealed that PNI ?0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88–4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16–1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02–0.55; p=0.035) were associated with poorer ORR. Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib. © 2022 Sociedade Portuguesa de PneumologiaÖğe Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer(Elsevier Science Inc, 2019) Bilici, A.; Olmez, O. F.; Gursoy, P.; Cubukcu, E.; Yildiz, O.; Sakin, A.; Hamdard, J.[No abstract available]
